

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark OfficeAddress: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/345,148 06/30/99 SEGAL

A 3378/804

1111/1220

HM12/0619

EXAMINER

GAMBEL, P

KATHLEEN M WILLIAM ESQ  
BANNER & WITCOFF LTD  
20 STATE STREET  
BOSTON MA 02109

ART UNIT

PAPER NUMBER

1644

DATE MAILED:

05/19


Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Docketed GreenResponse Due Respo to OAStatutory Period 7/19/01 (12/19/01 Final)Palmer & Dodge LLP  
Patent Department

RECEIVED

JUN 28 2001

Palmer & Dodge, LLP  
Patent Department



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

DEAFCE-1994

09/345148

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
1644	18

DATE MAILED:

**Pl ase find below a communication from the EXAMINER in charge of this application**  
Commissioner of Patents

Applicant's response filed 4/5/01 (Paper No. 10) is not fully responsive to the Restriction Requirement, mailed 11/27/00 (Paper No. 8). See 37 CFR 1.111.

Claims 69-70 have been added.

Applicant's election of Group I (claims 1-15, 28 and 29) and the species lipid linked CD40-specific antibody with traverse is acknowledged.

However applicant was required to elect a species from each of the following if Group I was elected.

This application contains claims directed to the following patentably distinct species of the claimed Groups I/II/III/IV/V/VI: wherein the CD40L enhanced cells or engineered CD40 ligand is/further comprises an CD40 ligand selected from the group consisting of:

- A) CD40 or
- ① → B) CD40-specific antibody.

This application contains claims directed to the following patentably distinct species of the claimed Groups I/II/III/IV/V/VI: wherein the CD40L enhanced cells or engineered CD40 ligand is/further comprises an opsonin selected from the group consisting of:

- A) mannose binding protein or
- ② → B) alpha chain of C3b.

This application contains claims directed to the following patentably distinct species of the claimed Groups I/II/III/IV/V/VI: wherein the CD40L enhanced cells or engineered CD40 ligand is/further comprises an opsonin selected from the group consisting of:

- A) mannose binding protein or
- ③ → B) alpha chain of C3b.

and IL-2

The reply filed on 9 is not fully responsive to the prior Office action because of the following omission(s) or matter(s):. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.



Phillip Gambel, PhD.  
Primary Examiner  
Technology Center 1600  
June 18, 2001

1601

**PALMER & DODGE LLP**111 HUNTINGTON AVENUE AT PRUDENTIAL CENTER  
BOSTON, MA 02199-7613**FAX**

sending \_\_\_\_ pages (including cover sheet)

<b>DATE</b>	December 19, 2001	<b>SENDER ID #</b>	1218
<b>FROM</b>	Matthew Beaudet, Ph.D.	<b>CLIENT #</b>	11111/1220
<b>DIRECT DIAL #</b>	(617) 239-0614		
<b>NAME</b>	<b>COMPANY</b>	<b>PHONE #</b>	<b>FAX #</b>
P. Gambel	U.S. Patent Office		703-305-3014

**COMMENTS:**

NOTICE OF CONFIDENTIALITY: This transmission is intended only for the addressee(s) listed above, and may contain information that is confidential and privileged. If you are not the addressee, any use, disclosure, copying or communication of the contents of this transmission may be subject to legal restrictions or sanctions. If this message was received in error, please telephone us immediately collect at 617.239.0122 and we will arrange for the return to us of this message at no cost to you.

This fax was transmitted via a group 3 machine.

REV 10/01

For Fax Problems, Please Call:(617) 239-0614

MAIN 617.239.0100 FAX 617.227.4420 [www.palmerdodge.com](http://www.palmerdodge.com)

12/19/01 WED 16:53 [TX/RX NO 9245]